Memòria Científica del Grup: 2017 Scientific Report – Genetics in Neurodegenerative Diseases
Memòria Científica del Grup: 2017 Scientific Report – Genetics in Neurodegenerative Diseases
FORTEA ORMAECHEA, JUAN FGS
jfortea@santpau.cat
Alcolea Rodriguez, Daniel Andres FGS
Altuna Azkargorta, Miren IR
Arranz Martinez, Javier Jose IR
Aumatell Escabias, Joaquim IR
Bejanin , Alexandre Pierre Armand IR
Carmona Iragui, Maria FGS
Dols Icardo, Oriol IR
El Bachiri Azzahchi, Sumia IR
El Bounasri El Bennadi, Shaimaa IR
Gimenez Badia, Sandra FGS
Illan Gala, Ignacio FGS
Iulita , Maria Florencia IR
Lleo Bisa, Alberto FGS
Lorente Gordillo, Oriol IR
Marques Kiderle, Sonia Karin IR
Montal Blancafort, Victor IR
Morcillo Nieto, Alejandra Omaira IR
Mota Rodriguez, Cecilia IR
Palmieri , Marisa Alejandra IR
Pegueroles Monllau, Jordi IR
Querol Vilaseca, Marta CIBERNED
Reyes Santiago, Daniel CIBERNED
Ribas Bellavista, Laia IR
Ribosa Nogue, Roser IR
Rodriguez Baz, Iñigo IR
Rozalem Aranha, Mateus IR
Rubio Guerra, Sara FGS
Sala Matavera, Isabel FGS
Sanchez Aced, Erika CIBERNED
Sanchez Lopez, Oriol CIBERNED
Sanchez Saudinos, Maria Belen IR
Santos Santos, Miguel Angel FGS
Sirisi Dolcet, Sonia IR
Subirana Castillo, Andrea IR
Torres Alcala, Soraya IR
Valldeneu Castells, Silvia IR
Valle Tamayo, Natalia IR
Vera Campuzano, Elena CIBERNED
Videla Toro, Laura IR
Zhu , Nuole FGS
Bartolome F, Krzyzanowska A, de la Cueva M, Pascual C, Antequera D, Spuch C, Villarejo-Galende A, Rabano A, Fortea J, Alcolea D, Lleo A, Ferrer I, Hardy J, Abramov AY, Carro E. Annexin A5 prevents amyloid-b-induced toxicity in choroid plexus: implication for Alzheimer’s disease. Sci Rep. 2020 Jun 10;10(1):9391. doi: 10.1038/s41598-020-66177-5.PMID: 32523019.
IF: 4,3790
Belbin O, Lehmann S, Sabidó E, Hirtz C. Editorial: Proteomics as a Tool for Biomarker and Drug Target Discovery: Improving the Diagnosis and Treatment of Neurodegenerative Diseases. Front Aging Neurosci. 2020 Nov 26;12:232. doi: 10.3389/fnagi.2020.00232. eCollection 2020.PMID: 33324192.
IF: 5,7500
Belbin O, Xiao MF, Xu D, Carmona-Iragui M, Pegueroles J, Benejam B, Videla L, Fernández S, Barroeta I, Nuñez-Llaves R, Montal V, Vilaplana E, Altuna M, Clarimón J, Alcolea D, Blesa R, Lleó A, Worley PF, Fortea J. Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer’s disease-related inhibitory circuit dysfunction in adults with Down syndrome. Mol Neurodegener. 2020 Aug 17;15(1):46. doi: 10.1186/s13024-020-00398-0.PMID: 32807227.
IF: 14,1950
Berthier ML, Dávila G, Torres-Prioris MJ, Moreno-Torres I, Clarimón J, Dols-Icardo O, Postigo MJ, Fernández V, Edelkraut L, Moreno-Campos L, Molina-Sánchez D, de Zaldivar PS, López-Barroso D. Developmental Dynamic Dysphasia: Are Bilateral Brain Abnormalities a Signature of Inefficient Neural Plasticity? Front Hum Neurosci. 2020 Mar 24;14:73. doi: 10.3389/fnhum.2020.00073. eCollection 2020.PMID: 32265672.
IF: 3,1690
Calabria M., Hernandez M., Cattaneo G., Suades A., Serra M., Juncadella M., Rene R., Sala I., Lleo A., Ortiz-Gil J., Ugas L., Avila A., Ruiz I.G., Avila C., Costa A. (2020) Active bilingualism delays the onset of mild cognitive impairment. NEUROPSYCHOLOGIA, 146 (), -.
IF: 3,1390
Cantero J.L., Atienza M., Lage C., Zaborszky L., Vilaplana E., Lopez-Garcia S., Pozueta A., Rodriguez-Rodriguez E., Blesa R., Alcolea D., Lleo A., Sanchez-Juan P., Fortea J. (2020) Atrophy of Basal Forebrain Initiates with Tau Pathology in Individuals at Risk for Alzheimer's Disease. CEREB CORTEX, 30 (4), 2083-2098.
IF: 5,3570
Cervera-Carles L., Dols-Icardo O., Molina-Porcel L., Alcolea D., Cervantes-Gonzalez A., Munoz-Llahuna L., Clarimon J. (2020) Assessing circular RNAs in Alzheimer's disease and frontotemporal lobar degeneration. NEUROBIOL AGING, 92 (), 7-11.
IF: 4,6730
Clarimón J. Genetic-environmental factors finally assessed together in Parkinson’s disease. J NEUROL NEUROSUR PS. 2020 Oct;91(10):1030. doi: 10.1136/jnnp-2020-324472.PMID: 32934106.
IF: 10,1540
Clarimon J., Moreno-Grau S., Cervera-Carles L., Dols-Icardo O., Sanchez-Juan P., Ruiz A. (2020) Genetic architecture of neurodegenerative dementias. NEUROPHARMACOLOGY, 168 (), -.
IF: 5,2500
Costa B, Manzoni C, Bernal-Quiros M, Kia DA, Aguilar M, Alvarez I, Alvarez V, Andreassen O, Anfossi M, Bagnoli S, Benussi L, Bernardi L, Binetti G, Blackburn D, Boada M, Borroni B, Bowns L, Bråthen G, Bruni AC, et al. C9orf72, age at onset, and ancestry help discriminate behavioral from language variants in FTLD cohorts. Neurology. 2020 Dec 15;95(24):e3288-e3302. doi: 10.1212/WNL.0000000000010914. Epub 2020 Sep 17. PMID: 32943482.
IF: 9,9100
de Gonzalo-Calvo D., Barroeta I., Nan M.N., Rives J., Garzon D., Carmona-Iragui M., Benejam B., Videla L., Fernandez S., Altuna M., Valldeneu S., Blesa R., Lleo A., Blanco-Vaca F., Fortea J., Tondo M. (2020) Evaluation of biochemical and hematological parameters in adults with Down syndrome. SCI REP-UK, 10 (1), -.
IF: 4,3790
De Luna N., Turon-Sans J., Cortes-Vicente E., Carrasco-Rozas A., Illan-Gala I., Dols-Icardo O., Clarimon J., Lleo A., Gallardo E., Illa I., Rojas-Garcia R. (2020) Downregulation of miR-335-5P in Amyotrophic Lateral Sclerosis Can Contribute to Neuronal Mitochondrial Dysfunction and Apoptosis. SCI REP-UK, 10 (1), -.
IF: 4,3790
Delaby C., Alcolea D., Carmona-Iragui M., Illan-Gala I., Morenas-Rodriguez E., Barroeta I., Altuna M., Estelles T., Santos-Santos M., Turon-Sans J., Munoz L., Ribosa-Nogue R., Sala-Matavera I., Sanchez-Saudinos B., Subirana A., Videla L., Benejam B., Sirisi S., Lehmann S., Belbin O., Clarimon J., Blesa R., Pagonabarraga J., Rojas-Garcia R., Fortea J., Lleo A. (2020) Differential levels of Neurofilament Light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders. SCI REP-UK, 10 (1), -.
IF: 4,3790
Dols-Icardo O., Montal V., Sirisi S., Lopez-Pernas G., Cervera-Carles L., Querol-Vilaseca M., Munoz L., Belbin O., Alcolea D., Molina-Porcel L., Pegueroles J., Turon-Sans J., Blesa R., Lleo A., Fortea J., Rojas-Garcia R., Clarimon J. (2020) Motor cortex transcriptome reveals microglial key events in amyotrophic lateral sclerosis. NEUROL-NEUROIMMUNOL, 7 (5), -.
IF: 8,4850
Faura J., Bustamante A., Penalba A., Giralt D., Simats A., Martinez-Saez E., Alcolea D., Fortea J., Lleo A., Teunissen C.E., van der Flier W.M., Ibanez L., Harari O., Cruchaga C., Hernandez-Guillamon M., Delgado P., Montaner J. (2020) CCL23: A Chemokine Associated with Progression from Mild Cognitive Impairment to Alzheimer's Disease. J ALZHEIMERS DIS, 73 (4), 1585-1595.
IF: 4,4720
Fortea J., Vilaplana E., Carmona-Iragui M., Benejam B., Videla L., Barroeta I., Fernandez S., Altuna M., Pegueroles J., Montal V., Valldeneu S., Gimenez S., Gonzalez-Ortiz S., Munoz L., Estelles T., Illan-Gala I., Belbin O., Camacho V., Wilson L.R., Annus T., Osorio R.S., Videla S., Lehmann S., Holland A.J., Alcolea D., Clarimon J., Zaman S.H., Blesa R., Lleo A. (2020) Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. LANCET, 395 (10242), 1988-1997.
IF: 79,3210
Hauser WA, Lleo A, Schmolck H. Dementia and epilepsy: Not a one-way street. Neurology. 2020 Dec 15;95(24):1074-1075. doi: 10.1212/WNL.0000000000011084. PMID: 33097601.
IF: 9,9100
Hernandez I, Gelpi E, Molina-Porcel L, Bernal S, Rodríguez-Santiago B, Dols-Icardo O, Ruiz A, Alcolea D, Boada M, Lleó A, Clarimón J. Heterozygous APOE Christchurch in familial Alzheimer’s disease without mutations in other Mendelian genes. NEUROPATH APPL NEURO. 2020 Oct 23. doi: 10.1111/nan.12670. Online ahead of print.PMID: 33095930.
IF: 8,0900
Hong S, Prokopenko D, Dobricic V, Kilpert F, Bos I, Vos SJB, Tijms BM, Andreasson U, Blennow K, Vandenberghe R, Cleynen I, Gabel S, Schaeverbeke J, Scheltens P, Teunissen CE, Niemantsverdriet E, et al. Genome-wide association study of Alzheimer’s disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset. Transl Psychiat. 2020 Nov 22;10(1):403. doi: 10.1038/s41398-020-01074-z. PMID: 33223526.
IF: 6,2220
Illán-Gala I, Montal V, Pegueroles J, Vilaplana E, Alcolea D, Dols-Icardo O, de Luna N, Turón-Sans J, Cortés-Vicente E, Martinez-Roman L, Sánchez-Saudinós MB, Subirana A, Videla L, Sala I, Barroeta I, Valldeneu S, Blesa R, Clarimón J, Lleó A, Fortea J, Rojas-García R. Cortical microstructure in the amyotrophic lateral sclerosis-frontotemporal dementia continuum. Neurology. 2020 Nov 3;95(18):e2565-e2576. doi: 10.1212/WNL.0000000000010727. Epub 2020 Sep 10. PMID: 32913016.
IF: 9,9100
Illán-Gala I, Lleo A, Karydas A, Staffaroni AM, Zetterberg H, Sivasankaran R, Grinberg LT, Spina S, Kramer J, Ramos EM, Coppola G, La Joie R, Rabinovici GD, Perry DC, Gorno-Tempini ML, Seeley W, Miller BL, Rosen HJ, Blennow K, Boxer AL, Rojas JC. Plasma tau and neurofilament light in frontotemporal lobar degeneration and Alzheimer’s disease. Neurology. 2020 Nov 16:10.1212/WNL.0000000000011226. doi: 10.1212/WNL.0000000000011226. Online ahead of print. PMID: 33199433.
IF: 9,9100
Kamer A.R., Craig R.G., Niederman R., Fortea J., de Leon M.J. (2020) Periodontal disease as a possible cause for Alzheimer's disease. PERIODONTOL 2000, 83 (1), 242-271.
IF: 7,5890
Konijnenberg E, Tijms BM, Gobom J, Dobricic V, Bos I, Vos S, Tsolaki M, Verhey F, Popp J, Martinez-Lage P, Vandenberghe R, Lleó A, Frölich L, Lovestone S, Streffer J, Bertram L, Blennow K, Teunissen CE, Veerhuis R, Smit AB, Scheltens P, Zetterberg H, Visser PJ. APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease. Alzheimers Res Ther. 2020 May 27;12(1):65. doi: 10.1186/s13195-020-00628-z. PMID: 32460813.
IF: 6,9820
Lawingco T, Chaudhury S, Brookes KJ, Guetta-Baranes T, Guerreiro R, Bras J, Hardy J, Francis P, Thomas A, Belbin O, Morgan K. Genetic variants in glutamate-, Aβ-, and tau-related pathways determine polygenic risk for Alzheimer’s disease. Neurobiol Aging. 2020 Nov 12:S0197-4580(20)30391-2. doi: 10.1016/j.neurobiolaging.2020.11.009. Online ahead of print. PMID: 33303219.
IF: 4,6730
Lehmann S, Dumurgier J, Ayrignac X, Marelli C, Alcolea D, Ormaechea JF, Thouvenot E, Delaby C, Hirtz C, Vialaret J, Ginestet N, Bouaziz-Amar E, Laplanche JL, Labauge P, Paquet C, Lleo A, Gabelle A; Alzheimer’s Disease Neuroimaging Initiative (ADNI). Cerebrospinal fluid A beta 1-40 peptides increase in Alzheimer’s disease and are highly correlated with phospho-tau in control individuals. Alzheimers Res Ther. 2020 Oct 2;12(1):123. doi: 10.1186/s13195-020-00696-1. PMID: 33008460.
IF: 6,9820
Leonard H, Blauwendraat C, Krohn L, Faghri F, Iwaki H, Ferguson G, Day-Williams AG, Stone DJ, Singleton AB, Nalls MA, Gan-Or Z; International Parkinson’s Disease Genomic Consortium (IPDGC). Genetic variability and potential effects on clinical trial outcomes: perspectives in Parkinson’s disease. J Med Genet. 2020; 57(5): 331-338. doi: 10.1136/jmedgenet-2019-106283. PMID: 31784483.
IF: 6,3180
Lidón L, Urrea L, Llorens F, Gil V, Alvarez I, Diez-Fairen M, Aguilar M, Pastor P, Zerr I, Alcolea D, Lleó A, Vidal E, Gavín R, Ferrer I, Del Rio JA. Disease-Specific Changes in Reelin Protein and mRNA in Neurodegenerative Diseases. Cells. 2020 May 19;9(5):1252. doi: 10.3390/cells9051252.PMID: 32438605.
IF: 6,6000
Lopez-Mora D.A., Fernandez Leon A., Lleo A., Blesa R., Camacho V. (2020) The Added Value of Tau-PET in the Assessment of Progressive Supranuclear Palsy. CLIN NUCL MED, 45 (5), E239-E240.
IF: 7,7940
Martín-Aguilar L, Camps-Renom P, Lleixà C, Pascual-Goñi E, Díaz-Manera J, Rojas-García R, De Luna N, Gallardo E, Cortés-Vicente E, Muñoz L, Alcolea D, Lleó A, Casasnovas C, Homedes C, Gutiérrez-Gutiérrez G, et al. Serum neurofilament light chain predicts long-term prognosis in Guillain-Barré syndrome patients. J Neurol Neurosurg Ps. 2020 Nov 5:jnnp-2020-323899. doi: 10.1136/jnnp-2020-323899. Online ahead of print. PMID: 33154183.
IF: 10,1540
Montal V, Vilaplana E, Pegueroles J, Bejanin A, Alcolea D, Carmona-Iragui M, Clarimón J, Levin J, Cruchaga C, Graff-Radford NR, Noble JM, Lee JH, Allegri R, Karch CM, Laske C, Schofield PR, Salloway S, Ances B, Benzinger T, McDale E, Bateman R, Blesa R, Sánchez-Valle R, Lleó A, Fortea J; Dominantly Inherited Alzheimer Network (DIAN). Biphasic cortical macro- and microstructural changes in autosomal dominant Alzheimer’s disease. Alzheimers Dement. 2020 Nov 16. doi: 10.1002/alz.12224. Online ahead of print. PMID: 33196147.
IF: 21,5660
Pascual-Goñi E, Fortea J, Martínez-Domeño A, Rabella N, Tecame M, Gómez-Oliva C, Querol L, Gómez-Ansón B. COVID-19-associated ophthalmoparesis and hypothalamic involvement. Neurol Neuroimmunol Neuroinflamm. 2020 Jun 25;7(5):e823. doi: 10.1212/NXI.0000000000000823. Print 2020 Sep. PMID: 32587102.
IF: 8,4850
Petersen ME, Rafii MS, Zhang F, Hall J, Julovich D, Ances BM, Schupf N, Krinsky-McHale SJ, Mapstone M, Silverman W, Lott I, Klunk W, Head E, Christian B, Foroud T, Lai F, Diana Rosas H, Zaman S, Wang MC, Tycko B, Lee J, Handen B, Hartley S, Fortea J, O’Bryant S; Alzheimer’s Biomarker Consortium –Down Syndrome (ABC-DS). Plasma Total-Tau and Neurofilament Light Chain as Diagnostic Biomarkers of Alzheimer’s Disease Dementia and Mild Cognitive Impairment in Adults with Down Syndrome. J Alzheimers Dis. 2020 Dec 16. doi: 10.3233/JAD-201167. Online ahead of print. PMID: 33337378.
IF: 2,0350
Rosas I., Martinez C., Clarimon J., Lleo A., Illan-Gala I., Dols-Icardo O., Borroni B., Almeida M.R., van der Zee J., Van Broeckhoven C., Bruni A.C., Anfossi M., Bernardi L., Maletta R., Serpente M., Galimberti D., Scarpini E., Rossi G., Caroppo P., Benussi L., Ghidoni R., Binetti G., Nacmias B., Sorbi S., Piaceri I., Bagnoli S., Antonell A., Sanchez-Valle R., De la Casa-Fages B., Grandas F., Diez-Fairen M., Pastor P., Ferrari R., Alvarez V., Menendez-Gonzalez M. (2020) Role for ATXN1, ATXN2, and HTT intermediate repeats in frontotemporal dementia and Alzheimer's disease. NEUROBIOL AGING, 87 (), 139.e1-139.e7.
IF: 4,6730
Sampedro F, Stantonyonge N, Martínez-Horta S, Alcolea D, Lleó A, Muñoz L, Pérez-González R, Marín-Lahoz J, Gómez-Ansón B, Chico A. Increased plasma neurofilament light chain levels in patients with type-1 diabetes with impaired awareness of hypoglycemia. BMJ Open Diab Res Care. 2020 Jul;8(1):e001516. doi: 10.1136/bmjdrc-2020-001516. PMID: 32636221.
IF: 3,3880
Shi L., Winchester L.M., Liu B.Y., Killick R., Ribe E.M., Westwood S., Baird A.L., Buckley N.J., Hong S., Dobricic V., Kilpert F., Franke A., Kiddle S., Sattlecker M., Dobson R., Cuadrado A., Hye A., Ashton N.J., Morgan A.R., Bos I., Vos S.J.B., Ten Kate M., Scheltens P., Vandenberghe R., Gabel S., Meersmans K., Engelborghs S., De Roeck E.E., Sleegers K., Frisoni G.B., Blin O., Richardson J.C., Bordet R., Molinuevo J.L., Rami L., Wallin A., Kettunen P., Tsolaki M., Verhey F., Lleo A., Alcolea D., Popp J., Peyratout G., Martinez-Lage P., Tainta M., Johannsen P., Teunissen C.E., Freund-Levi Y., Frolich L., Legido-Quigley C., Barkhof F., Blennow K., Rasmussen K.L., Nordestgaard Bo.G., Frikke-Schmidt R., Nielsen S.F., Soininen H., Vellas B., Kloszewska I., Mecocci P., Zetterberg H., Morgan B.P., Streffer J., Visser P.J., Bertram L., Nevado-Holgado A.J., Lovestone S. (2020) Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. J ALZHEIMERS DIS, 77 (3), 1353-1368.
IF: 4,4720
Snyder H.M., Bain L.J., Brickman A.M., Carrillo M.C., Esbensen A.J., Espinosa J.M., Fernandez F., Fortea J., Hartley S.L., Head E., Hendrix J., Kishnani P.S., Lai F., Lao P., Lemere C., Mobley W., Mufson E.J., Potter H., Zaman S.H., Granholm A.-C., Rosas H.D., Strydom A., Whitten M.S., Rafii M.S. (2020) Further understanding the connection between Alzheimer's disease and Down syndrome. ALZHEIMERS DEMENT, 16 (7), 1065-1077.
IF: 21,5660
Tijms B.M., Gobom J., Reus L., Jansen I., Hong S., Dobricic V., Kilpert F., Ten Kate M., Barkhof F., Tsolaki M., Verhey F.R.J., Popp J., Martinez-Lage P., Vandenberghe R., Lleo A., Molinuevo J.L., Engelborghs S., Bertram L., Lovestone S., Streffer J., Vos S., Bos I., Blennow K., Scheltens P., Teunissen C.E., Zetterberg H., Visser P.J. (2020) Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics. BRAIN, 143 (12), 3776-3792.
IF: 13,5010
Tort-Merino A, Laine M, Valech N, Olives J, León M, Ecay-Torres M, Estanga A, Martínez-Lage P, Fortea J, Sánchez-Valle R, Rami L, Rodríguez-Fornells A. Accelerated long-term forgetting over three months in asymptomatic APOE 4 carriers. Ann Clin Transl Neur. 2020 Dec 25. doi: 10.1002/acn3.51245. Online ahead of print. PMID: 33369208.
IF: 4,5110
Van der Lee SJ, Conway OJ, Jansen I, Carrasquillo MM, Kleineidam L, van den Akker E, Hernández I, van Eijk KR, Stringa N, Chen JA, Zettergren A, Andlauer TFM, Diez-Fairen M, Simon-Sanchez J, Lleó A, Zetterberg H, et al. Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. Acta Neuropathol. 2020; 139(5): 959-962. doi: 10.1007/s00401-019-02107-8. PMID:31955222.
IF: 17,0880
Veerabhadrappa B., Delaby C., Hirtz C., Vialaret J., Alcolea D., Lleo A., Fortea J., Santosh M.S., Choubey S., Lehmann S. (2020) Detection of amyloid beta peptides in body fluids for the diagnosis of alzheimer’s disease: Where do we stand?. CRIT REV CL LAB SCI, 57 (2), 99-113.
IF: 6,2500
Vilaplana E, Rodriguez-Vieitez E, Ferreira D, Montal V, Almkvist O, Wall A, Lleó A, Westman E, Graff C, Fortea J, Nordberg A. Cortical microstructural correlates of astrocytosis in autosomal-dominant Alzheimer disease. Neurology. 2020 May 12;94(19):e2026-e2036. doi: 10.1212/WNL.0000000000009405. PMID: 32291295.
IF: 9,9100
Westwood S., Baird A.L., Anand S.N., Nevado-Holgado A.J., Kormilitzin A., Shi L., Hye A., Ashton N.J., Morgan A.R., Bos I., Vos S.J.B., Baker S., Buckley N.J., Ten Kate M., Scheltens P., Teunissen C.E., Vandenberghe R., Gabel S., Meersmans K., Engelborghs S., De Roeck E.E., Sleegers K., Frisoni G.B., Blin O., Richardson J.C., Bordet R., Molinuevo J.L., Rami L., Wallin A., Kettunen P., Tsolaki M., Verhey F., Lleo A., Sala I., Popp J., Peyratout G., Martinez-Lage P., Tainta M., Johannsen P., Freund-Levi Y., Frolich L., Dobricic V., Legido-Quigley C., Bertram L., Barkhof F., Zetterberg H., Morgan B.P., Streffer J., Visser P.J., Lovestone S. (2020) Validation of plasma proteomic biomarkers relating to brain amyloid burden in the EMIF-Alzheimer's disease multimodal biomarker discovery cohort. J ALZHEIMERS DIS, 74 (1), 213-225.
IF: 4,4720